Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 9/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8611395 | 0.93 | EPHX2 (0.39) | HDAC3HDAC6EPHX2 | |
| SCHEMBL13090205 | 0.92 | EPHX2 (0.40) | HDAC1HDAC3HDAC4HDAC6PPARA | |
| SCHEMBL15259119 | 0.92 | HDAC1 (0.39) | HDAC1HDAC3HDAC4HDAC6PPARA | |
| SCHEMBL8577061 | 0.90 | HDAC3 (0.41) | HDAC1HDAC3HDAC4HDAC6PPARA | |
| SCHEMBL13090243 | 0.89 | EPHX2 (0.39) | HDAC1HDAC3HDAC4HDAC6PPARA | |
| SCHEMBL8612322 | 0.89 | KMT2A (0.35) | HDAC1HDAC3HDAC4HDAC6CHRM4 | |
| SCHEMBL8578519 | 0.89 | MEN1 (0.39) | — | |
| SCHEMBL13090175 | 0.89 | HDAC1 (0.35) | HDAC1HDAC3HDAC4HDAC6PPARA | |
| SCHEMBL8578536 | 0.88 | HDAC3 (0.45) | HDAC1HDAC3HDAC4HDAC6CHRM4 | |
| SCHEMBL13090215 | 0.86 | F10 (0.46) | HDAC1HDAC3HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | HDAC1 135/4885HDAC3 116/4885HDAC4 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.